Fig. 4. SC144@HABN and anti-PD-L1 combo therapy induces robust anti-tumor immunity.

a–k C57BL/6 mice bearing MC38 tumor were administered IV with SC144 (5 mg/kg), HABN (50 mg/kg) SC144@HABN (5 mg/kg of SC144; 50 mg/kg of HABN), or PBS on days 11, 13, and day 15 with or without intraperitoneal administration of anti-mouse PD-L1 (5 mg/kg) on days 12, 14, and 16. For TME analysis, tumor was excised on day 18, and flow cytometry was performed. b MC38 tumor growth curves and c, survival of mice treated with the indicated formulations. d–j Shown are the frequencies of intratumoral CD45⁺CD3⁺CD8⁺ T-cells (d), CD45⁺CD3⁺CD8⁺Ki67⁺ T-cells (e), CD45⁺CD3⁺CD8⁺Granzyme B⁺ T-cells (f), CD45⁺CD3⁺CD8⁺PD-1⁺ T-cells (g), CD45⁺CD3⁺CD4⁺Foxp3⁺ T-cells (h), CD45^-PD-L1⁺ cells (i), CD45⁺CD11b⁺F4/80⁺ TAMs (j, left panel), and CD45⁺CD11b⁺ F4/80^- MDSCs (j, right panel). k Shown are the frequency of CD45⁺CD11b⁺F4/80⁺MHC⁺ M1-like macrophages, CD45⁺CD11b⁺F4/80⁺ CD206⁺ M2-like macrophages, and their ratio. l, m Tumor-free survivors were inoculated with MC38 cells and tumor volume (l) and survival percentages (m) were measured. The data represent mean ± s.e.m., biological replicates with n = 4 (l, m) or 5 (a–k). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, analyzed by two-way ANOVA (b, l, m), or one-way ANOVA (d–k) with Tukey’s HSD multiple comparison post hoc test, or Kaplan–Meier survival analysis with the log-rank (Mantel–Cox) test (c). Source data are provided as a Source data file.